Wermke, M., Klein, S., & Hofmann, W. (2018). Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): A prospective, multicentre, observational trial. The lancet. Haematology, 5(5), . https://doi.org/10.1016/S2352-3026(18)30036-X
Chicago-Zitierstil (17. Ausg.)Wermke, Martin, Stefan Klein, und Wolf-Karsten Hofmann. "Enhanced Labile Plasma Iron and Outcome in Acute Myeloid Leukaemia and Myelodysplastic Syndrome After Allogeneic Haemopoietic Cell Transplantation (ALLIVE): A Prospective, Multicentre, Observational Trial." The Lancet. Haematology 5, no. 5 (2018). https://doi.org/10.1016/S2352-3026(18)30036-X.
MLA-Zitierstil (9. Ausg.)Wermke, Martin, et al. "Enhanced Labile Plasma Iron and Outcome in Acute Myeloid Leukaemia and Myelodysplastic Syndrome After Allogeneic Haemopoietic Cell Transplantation (ALLIVE): A Prospective, Multicentre, Observational Trial." The Lancet. Haematology, vol. 5, no. 5, 2018, https://doi.org/10.1016/S2352-3026(18)30036-X.